Abstract
We report our experience with hematin in the treatment of 57 patients in porphyric attacks. The ratio of acute intermittent porphyria: variegate porphyria: hereditary coproporphyria was 43:11:3. More than 90% of the patients showed not only a decline in their porphyrin precursors, but also a favorable clinical response. Hematin was well tolerated and should be considered the treatment of choice in porphyric relapse.
Original language | English (US) |
---|---|
Pages (from-to) | 829-832 |
Number of pages | 4 |
Journal | Klinische Wochenschrift |
Volume | 58 |
Issue number | 16 |
DOIs | |
State | Published - Aug 1980 |
Keywords
- Hematin
- Porphyria
- Porphyrin precursors